PGS Sample Set (PSS): PSS000852

Phenotype Cases = number of all cause deaths. HFPGR: Patients with left ventricular ejection fraction (LVEF) <50% were included. Beta-blocker (BB) exposure was calculated from pharmacy claims (ie, drug actually dispensed to patient) and was updated over time. Beta-blocker (BB) exposure was calculated from pharmacy claims (ie, drug actually dispensed to patient) and was updated over time. TIME-CHF: Patients with analysable data and a baseline LVEF <50% were included. BB exposure was calculated from the specific drug and dose at baseline, using the same dose-equivalence scheme as HFPGR but implemented without any updates over time and without information on medication dispensing (ie, assumes patients were receiving the dose prescribed). HF-ACTION: BB exposure was calculated from the specific drug and dose at baseline, using the same dose-equivalence scheme as HFPGR but implemented without any updates over time and without information on medication dispensing (ie, assumes patients were receiving the dose prescribed).
Sample Ancestry European

Sample Numbers

Total number
1,188 individuals
Detailed numbers
279 cases (23.48%)
909 controls
Number of Cohort(s) 3
Sample distribution

Cohort(s)

Cohort Short Name Cohort Full Name Previous/other/additional names (e.g. sub-cohorts)
HF-ACTION Heart Failure: a Controlled Trial Investigating Outcomes of Exercise Training
HFPGR Henry Ford Heart Failure Pharmacogenomic Registry
TIME-CHF Trial of Intensified Versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure